- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Cases selected for the AskAnzal weekly PMCPA insight newsletter
A pharmacist challenged claims that Versatis was comparable to pregabalin (and possibly gabapentin) and had fewer side-effects/interactions. The…
GSK and Roche withdrew Bonviva ‘Building Bones’ materials after an undertaking, but Pulse republished the old ad. Panel…
Actiq ad and leavepiece implied breakthrough cancer pain control could be switched “on” and “off” like an appliance.…
Anonymous ex-employee alleged UK doctors were invited to a “lavish” Berlin meeting based on prescribing and that hospitality/entertainment…
Shire challenged Norgine’s ‘NICE recommends MOVICOL Paediatric Plain FIRST-LINE’ ad/leavepiece as unauthorised, unreferenced and implying off-label paediatric use.…
PMCPA case AUTH/3119/11/18 (Director v Pfizer) about clinical trial disclosure. The matter was ruled outwith the scope of…
A GP alleged Trajenta “with a difference” claims were misleading vs other DPP-4 inhibitors (dose adjustment, renal monitoring,…
A pharmacist alleged Leo’s pre-printed ‘Dear Dr’ forms for Picato were used to bypass local formulary status. PMCPA…
PMCPA found Bayer’s DMO e-detailer/briefing implied Eylea superiority vs Lucentis using unlicensed Lucentis dosing without clear status. Breaches…
Ferring was found in breach for late disclosure of one Firmagon trial result (NCT00116753). Other trials were either…
One real case. One key lesson. Every week — free.